Atea Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Atea Pharmaceuticals

09/08/2023 01:47

* Atea Pharmaceuticals Inc  AVIR.OQ  reported a quarterly
adjusted
loss of 34 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 47 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 34 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Atea Pharmaceuticals Inc shares had fallen by 9.1% this
quarter and lost 29.3% so far this year.
    * The company reported a quarterly loss of $28.18 million.
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $4.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 12:46 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.47          -0.34          Beat
 Mar. 31 2023      -0.48          -0.43          Beat
 Dec. 31 2022      -0.45          -0.41          Beat
 Sep. 30 2022      -0.44          -0.10          Beat